Dublin, Nov. 23, 2016 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Bipolar Disorder: Epidemiology and Patient-Based Market Forecasts, Treatment Algorithm, and Marketed and Pipeline Drug Analysis" report to their offering.

Generic dominance will prevent the growth of the bipolar disorder market, and few pipeline candidates show promise to completely reverse this trend.

This report addresses the following questions:

- What are the key events shaping the bipolar disorder market dynamics over 2014-23?
- Which segments of the market provide opportunities for growth?
- How does the bipolar disorder pipeline compare to other psychiatric indications, and what are the candidates to look out for?
- How do currently available bipolar disorder drugs compare to one another?
- What is the standard of care in bipolar disorder, and which are the key unmet needs in treatment?

Key Topics Covered:

FORECAST: BIPOLAR DISORDER

- Executive Summary
- Market Overview and Trends
- Market Definition and Methodology
- Abilify (aripiprazole)
- Abilify Maintena (aripiprazole)
- Latuda (lurasidone)
- Risperdal Consta (risperidone)
- Saphris (asenapine)
- Seroquel/Seroquel XR (quetiapine fumarate)
- Vraylar (cariprazine)
- Primary Research Methodology

TREATMENT: BIPOLAR DISORDER

- Executive Summary
- Primary Research Methodology,
- Disease Definition and Diagnosis
- Patient Segmentation
- Country Treatment Trees
- Current Treatment Options
- Prescribing Trends
- Unmet Needs in Bipolar Disorder

EPIDEMIOLOGY: BIPOLAR DISORDER IN THE US, JAPAN, AND 5EU

- Executive Summary
- Disease Definition
- Global Variation
- Risk Factors
- Co-Morbidities
- Sources and Methodology
- Forecast
- Forecast: Bipolar Disorder I
- Forecast: Bipolar Disorder II
- Epidemiologist Insight
- Strengths and Limitations
- Bibliography

MARKETED DRUGS: BIPOLAR DISORDER

- Executive Summary
- Product Overview
- Other Marketed Drugs
- Product profile: Abilify
- Product profile: Geodon
- Product profile: Lamictal
- Product profile: Latuda
- Product profile: Risperdal/Risperdal Consta
- Product profile: Saphris
- Product profile: Seroquel/Seroquel XR
- Product profile: Vraylar
- Product profile: Zyprexa

PIPELINE: BIPOLAR DISORDER

- Executive Summary
- Clinical Pipeline Overview
- Target Product Profile
- Clinical Trial Design
- The Future of Treatment
- Recently Discontinued Drugs
- Product profile (late stage): ITI-007

For more information about this report visit http://www.researchandmarkets.com/research/d2fd69/bipolar_disorder

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716
         Related Topics: Mental Health , Mental Disorders Drugs 

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.